Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial—a study protocol

Table 1 Inclusion and exclusion criteria for the ABLATIVE-2 trial

Inclusion criteria	Exclusion Criteria
World Health Organization performance status 0–2	Legal incapacity
Females ≥ 50 years with a unifocal cT1N0 tumor	Breast cancer mutation gene carrier
Tumor histology as assessed on biopsy:	Distant metastasis
- Bloom-Richardson grade 1 or 2	Previous history of breast cancer or DCIS
- Non-lobular invasive histological type carcinoma	Another type of malignancy within 5 years before breast cancer diagnosis^a
- Estrogen receptor positivity - HER2 receptor negativity	Signs of extensive ductal carcinoma in situ on histological biopsy or imaging
Tumor-negative sentinel node	MRI contra-indication
Adequate understanding of the Dutch language	Collagen synthesis disease
	Indication for treatment with (neo-)adjuvant chemotherapy
	Non-feasible dosimetric plan

^aFor patients with adequately treated carcinoma in situ of the cervix or basal cell carcinoma of the skin no specific time to the breast cancer diagnosis is required for inclusion. DCIS ductal carcinoma in situ

ISSN: 1471-2407